Everence Capital Management Inc. Has $574,000 Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Everence Capital Management Inc. lowered its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 48.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 2,920 shares of the medical research company’s stock after selling 2,778 shares during the period. Everence Capital Management Inc.’s holdings in IQVIA were worth $574,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Capital Performance Advisors LLP purchased a new position in shares of IQVIA during the third quarter valued at approximately $27,000. Park Place Capital Corp bought a new position in IQVIA during the 3rd quarter valued at $28,000. Itau Unibanco Holding S.A. purchased a new position in IQVIA during the 2nd quarter worth $29,000. International Assets Investment Management LLC purchased a new stake in shares of IQVIA in the second quarter valued at about $32,000. Finally, Avior Wealth Management LLC lifted its position in shares of IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 87 shares in the last quarter. 89.62% of the stock is owned by institutional investors.

IQVIA Stock Up 1.2 %

Shares of IQV opened at $197.39 on Friday. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The stock has a 50 day simple moving average of $202.86 and a two-hundred day simple moving average of $222.01. The firm has a market cap of $35.83 billion, a P/E ratio of 25.90, a P/E/G ratio of 2.05 and a beta of 1.49.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on IQV shares. Evercore ISI reduced their price objective on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. William Blair reaffirmed an “outperform” rating on shares of IQVIA in a research report on Wednesday, December 11th. Truist Financial cut their price objective on IQVIA from $265.00 to $261.00 and set a “buy” rating on the stock in a research report on Thursday, December 12th. Robert W. Baird reduced their price target on shares of IQVIA from $213.00 to $212.00 and set a “neutral” rating for the company in a research report on Wednesday, December 11th. Finally, TD Cowen cut their price target on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $255.82.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.